Intellia Therapeutics, Inc. - Common Stock — Financial Statements (NASDAQ:NTLA) | MetaTrader

Open full chart

News

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

The Disinflation Trade Has A New Address: Genomics

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics Stock: Steady Progress, Historic Commercial Approval (NASDAQ:NTLA)

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?